Survey identifies risk factor for French companies:
This article was originally published in Clinica
Executive Summary
One in six French medical device companies is at high risk of failure. That is the conclusion of a financial analysis compiled by UK company Plimsoll Publishing, which added that many companies in this category would struggle to settle payments with overseas suppliers. On the other side of the coin, 238 of this survey of the 350 most important manufacturers and retailers of medical devices are "financially sound and would be ideal companies with whom to do business". For more details of the survey, contact Plimsoll Publishing in Middlesborough, UK. Tel: +44 (0) 1642 257 809. Fax: +44 (0)1642 257 806.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.